Isolation and Characterization of Novel Degradation Products of Eliglustat Tartrate Using 2D-NMR and HRMS: Development and Validation of Stability Indicating RP-UPLC Method for Quantification of Assay and Characterized Impurities

References

• Rosenbloom, B.E., Weinerb, NJ. (2013). Gaucher Disease: a comprehensive review. Crit. Rev. Oncog. 18(3): 163-175. doi: 10.1615/CritRevOncog.2013006060
   PubMedGoogle Scholar
• Deegan, P.B., Cox, T.M. (2012). Imiglucrease in the treatment of Gaucher disease, a history and perspective. Drug. Des. Devel. Ther. 6: 81-106.
   PubMed Web of Science ®Google Scholar
• Scott, L.J. (2015). Eliglustat: A Review in Gaucher Disease Type 1, Drugs. 75(14): 1669-1678. doi: 10.1007/s40265-015-0468-9
   PubMed Web of Science ®Google Scholar
• Venier, R.E., Igdoura, S.A. (2012). Eliglustat as a therapeutic agent, prospects and caveats. J. Med. Genet. 49(9): 591-597. doi: 10.1136/jmedgenet-2012-101070
   PubMed Web of Science ®Google Scholar
• Smid, B.E. and Hollak, C.E. (2014). A systematic review on effectiveness and safety of eliglustat for type 1 Gaucher disease, Expert Opinion on Orphan Drugs. 2(5): 523-529. doi: 10.1517/21678707.2014.899148
   Web of Science ®Google Scholar
• US Food and Drug Administration. (2014). FDA approves new drug to treat a form of Gaucher disease [media release]. 19 Aug.
   Google Scholar
• Wang, R.Y., Bodamer, O.A., Watson, M.S., et al. (2011). Lysosomal storage diseases: diagnostic confirmation and management of pre symptomatic individuals, Genet Med. 13(5): 457–84. doi: 10.1097/GIM.0b013e318211a7e1
   PubMed Web of Science ®Google Scholar
• Poole Raewyn, M. (2014). Eliglustat: First global approval. Drugs. 74(15): 1829-1836. doi: 10.1007/s40265-014-0296-3
   PubMed Web of Science ®Google Scholar
• Tazeen, A., Vani, R. and Sunitha, M. (2017). Analytical method development and validation for the estimation of eliglustat using RP-HPLC method in bulk and pharmaceutical dosage form, Indo American Journal of Pharmaceutical Research. 7(11): 920-927.
   Google Scholar
• Umamaheshwar Puppala, Koduri S.V. Srinivas, K. Venkateshwara Reddy, Muralidharan Kaliyaperumal, Srinivasa Rao Pakalapati (2019). Enantiospecific UPC2 SFC-MS Method for Separation and Quantification of R & S-Eliglustat tartrate in Presence of its stereo isomers and degradation impurities, Materials Today: Proceedings, 19: 420-428.
   Google Scholar
• Nageswara Rao, R., Kuntamukkala, R. (2014). LC-MS/MS characterization of forced degradation products of ambrisentan: development and validation of a stability-indicating RP-HPLC method. New Journal of Chemistry, 38(7), pp. 3050-3061. doi: 10.1039/c4nj00075g
   Web of Science ®Google Scholar
• G. Mahesh Kumar Reddy, Jcmknn Murty Singamsetti, Muralidharan Kaliyaperumal, Raju Doddipalla, Ramu Ivaturi, Chidananda Swamy Rumalla, Raghu Babu Korupolu and B. Kishore Babu. (2020). Degradation studies of levosimendan isolation, identification, and structure confirmation of stress degradation products using LCMS, mass mediated Prep-HPLC, NMR, HRMS, SFC and FTIR. Journal of Liquid Chromatography & Related Technologies, 43(1-2), 17-28. doi: 10.1080/10826076.2019.1613429
   Google Scholar
• Fenghe Qiu, Daniel L. Norwood. (2007). Identification of Pharmaceutical Impurities, Journal of Liquid Chromatography & Related Technologies. 30(5-7): 877-935. doi: 10.1080/10826070701191151
   Web of Science ®Google Scholar
• Kushwaha, M., Goel, B., Jaglan, S. (2019). LC-MS/MS profile of an active pharmaceutical ingredient and its impurities in commercial preparation, Journal of Liquid Chromatography & Related Technologies, DOI: 10.1080/10826076.2019.1680561.
   Web of Science ®Google Scholar
• ICH guideline (2003). Q1A (R2) Stability Testing of New Drug Substances and Products, International Conference on Harmonisation, IFPMA, Geneva, Switzerland.
   Google Scholar
• International Conferences on Harmonization Q2 (R1). (2005). Validation of analytical procedures: text and methodology.
   Google Scholar
• Ngwa, G. (2010). Forced degradation studies as an integral part of HPLC stability indicating method development, Drug Delivery and Technology. 10 (5):56-59.
   Google Scholar
• Alsante, K.M., Ando, A., Brown, R. (2007). The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv. Drug Deliv. Rev, 59 (1): 29-37. doi: 10.1016/j.addr.2006.10.006
   PubMed Web of Science ®Google Scholar
• Singh, R., Rehman, Z. (2012). Current trends in forced degradation study for pharmaceutical product development. J. Pharm. Educ. Res., 3 (1): 54-63.
   Google Scholar